Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu +10 more
wiley +1 more source
Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang +4 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study. [PDF]
PLoS OneAvsar FN, Kılıcaslan N, Sahutoglu T.
europepmc +1 more source
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review
, 2013 Israa Al-Shakarchi, Nicola J Gullick, David L ScottDepartment of Rheumatology, Kings College Hospital, London, UKAbstract: Rheumatoid arthritis (RA) remains a major clinical problem with many patients having continuing systemic inflammatory disease ...
Scott DL, Al-Shakarchi I, Gullick NJ
core
Nomogram-based prediction model for tocilizumab-induced leukopenia in adults using FAERS and PMDA data. [PDF]
Braz J Med Biol ResWang L, Zhang X, Bao X, Chen Y, Yuan H.
europepmc +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli +10 more
wiley +1 more source
Tocilizumab Therapy and Incident Depression in Rheumatoid Arthritis: A Retrospective Cohort Study of the All of Us Research Program. [PDF]
CureusLehrer S, Rheinstein P.
europepmc +1 more source